{"as_of":"2026-10-13T22:18:44.590Z","query":{"query.spons":"Amgen","filter.overallStatus":"RECRUITING"},"count":20,"trials":[{"nct_id":"NCT07700238","title":"A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":126,"start_date":"2026-08-21","completion_date":"2029-10-14","conditions":["Primary Immune Thrombocytopenia"],"url":"https://clinicaltrials.gov/study/NCT07700238"},{"nct_id":"NCT05909761","title":"Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy","status":"RECRUITING","phases":[],"study_type":"OBSERVATIONAL","lead_sponsor":"Amgen","enrollment":60,"start_date":"2026-10-15","completion_date":"2032-10-31","conditions":["Neuromyelitis Optica Spectrum Disorder","Pregnancy Related"],"url":"https://clinicaltrials.gov/study/NCT05909761"},{"nct_id":"NCT07111507","title":"A Study of Tarlatamab for People With Prostate Cancer","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Memorial Sloan Kettering Cancer Center","enrollment":32,"start_date":"2025-07-31","completion_date":"2027-08-31","conditions":["Metastatic Prostate Cancer"],"url":"https://clinicaltrials.gov/study/NCT07111507"},{"nct_id":"NCT07438405","title":"An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":30,"start_date":"2026-05-07","completion_date":"2028-07-14","conditions":["Thyroid Eye Disease"],"url":"https://clinicaltrials.gov/study/NCT07438405"},{"nct_id":"NCT06747949","title":"A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":844,"start_date":"2025-02-25","completion_date":"2029-12-11","conditions":["Sjögren's Syndrome"],"url":"https://clinicaltrials.gov/study/NCT06747949"},{"nct_id":"NCT06883305","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"AstraZeneca","enrollment":990,"start_date":"2025-03-18","completion_date":"2029-06-05","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"url":"https://clinicaltrials.gov/study/NCT06883305"},{"nct_id":"NCT06471036","title":"Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?","status":"RECRUITING","phases":["NA"],"study_type":"INTERVENTIONAL","lead_sponsor":"Duke University","enrollment":400,"start_date":"2024-10-08","completion_date":"2027-02-28","conditions":["ASCVD","LDL-C"],"url":"https://clinicaltrials.gov/study/NCT06471036"},{"nct_id":"NCT07423585","title":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Asrar Alahmadi","enrollment":39,"start_date":"2026-03-20","completion_date":"2027-12-31","conditions":["Extensive Stage Lung Small Cell Carcinoma"],"url":"https://clinicaltrials.gov/study/NCT07423585"},{"nct_id":"NCT06072482","title":"A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis","status":"RECRUITING","phases":["PHASE4"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":300,"start_date":"2024-02-07","completion_date":"2036-12-31","conditions":["Antineutrophil Cytoplasmic Antibody-associated Vasculitis"],"url":"https://clinicaltrials.gov/study/NCT06072482"},{"nct_id":"NCT07851220","title":"A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":159,"start_date":"2026-10-01","completion_date":"2033-09-26","conditions":["Glomerulonephritis, Membranous"],"url":"https://clinicaltrials.gov/study/NCT07851220"},{"nct_id":"NCT04804553","title":"Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":60,"start_date":"2022-03-17","completion_date":"2028-12-29","conditions":["Active Juvenile Psoriatic Arthritis"],"url":"https://clinicaltrials.gov/study/NCT04804553"},{"nct_id":"NCT03263572","title":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"M.D. Anderson Cancer Center","enrollment":90,"start_date":"2017-11-29","completion_date":"2027-11-30","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","BCR-ABL1 Fusion Protein Expression","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive","Recurrent Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia","t(9;22)"],"url":"https://clinicaltrials.gov/study/NCT03263572"},{"nct_id":"NCT06613100","title":"Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer","status":"RECRUITING","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":40,"start_date":"2024-11-25","completion_date":"2030-03-04","conditions":["Prostate Cancer"],"url":"https://clinicaltrials.gov/study/NCT06613100"},{"nct_id":"NCT02622581","title":"Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients","status":"RECRUITING","phases":[],"study_type":"OBSERVATIONAL","lead_sponsor":"AIO-Studien-gGmbH","enrollment":14500,"start_date":"2015-12","completion_date":"2031-09","conditions":["Metastatic Non-small Cell Lung Cancer (NSCLC)","Non-small Cell Lung Cancer Metastatic","Non-small Cell Lung Cancer Stage II","Non Small Cell Lung Cancer Stage III","Small-cell Lung Cancer","Non-small Cell Lung Cancer Stage I"],"url":"https://clinicaltrials.gov/study/NCT02622581"},{"nct_id":"NCT06570798","title":"A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":220,"start_date":"2025-07-16","completion_date":"2028-08-06","conditions":["Systemic Lupus Erythematosus","Active Refractory Rheumatoid Arthritis"],"url":"https://clinicaltrials.gov/study/NCT06570798"},{"nct_id":"NCT04307576","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Mats Heyman","enrollment":6430,"start_date":"2020-07-13","completion_date":"2033-06","conditions":["Leukemia, Acute Lymphoblastic"],"url":"https://clinicaltrials.gov/study/NCT04307576"},{"nct_id":"NCT07293260","title":"Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":406,"start_date":"2026-03-23","completion_date":"2028-06-15","conditions":["Cardiovascular Disease"],"url":"https://clinicaltrials.gov/study/NCT07293260"},{"nct_id":"NCT04746209","title":"Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Medical College of Wisconsin","enrollment":25,"start_date":"2021-02-01","completion_date":"2029-12-31","conditions":["B-cell Acute Lymphoblastic Leukemia","B-cell Childhood Acute Lymphoblastic Leukemia","B-Cell ALL, Childhood"],"url":"https://clinicaltrials.gov/study/NCT04746209"},{"nct_id":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","enrollment":40,"start_date":"2025-07-02","completion_date":"2030-01-15","conditions":["Metastatic/Locally Advanced Small-Cell Lung Cancer","Metastatic/Locally Advanced Poorly Differentiated NEC"],"url":"https://clinicaltrials.gov/study/NCT07016230"},{"nct_id":"NCT07684144","title":"Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)","status":"RECRUITING","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"Amgen","enrollment":950,"start_date":"2026-07-29","completion_date":"2028-03-19","conditions":["Obesity","Overweight","Diabetes Mellitus, Type 2"],"url":"https://clinicaltrials.gov/study/NCT07684144"}],"source":"Source: National Library of Medicine (ClinicalTrials.gov)","disclaimer":"Courtesy of the National Library of Medicine (ClinicalTrials.gov), retrieved at as_of; distributions and totals are computed by AnswerPool. Registry entries are submitted by sponsors and reflect what was registered, not verified outcomes. Not medical advice.","refresh_after":"2026-10-14T00:00:00.000Z"}